{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:53:55Z","timestamp":1678560835873},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.lungcan.2007.02.003","type":"journal-article","created":{"date-parts":[[2007,3,27]],"date-time":"2007-03-27T07:17:26Z","timestamp":1174979846000},"page":"66-71","source":"Crossref","is-referenced-by-count":12,"title":["Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: A phase I-II trial"],"prefix":"10.1016","volume":"57","author":[{"given":"George P.","family":"Stathopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Dimitroulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Toubis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costas","family":"Katis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitris","family":"Karaindros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Koutandos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2007.02.003_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/978-1-4615-2960-6_80","article-title":"Design and synthesis of inhibitors of folate-dependent enzymes as antitumor agents","volume":"338","author":"Taylor","year":"1993","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib2","first-page":"1116","article-title":"LY231514, a pyrrolo (2,3-d) pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes","volume":"57","author":"Shih","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2007.02.003_bib3","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002800050992","article-title":"A phase I evaluation of multitargeted antifolate (MTA, LY231514) administered every 21 days using the modified continual reassessment method for dose escalation","volume":"44","author":"Rinaldi","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.1999.17.2.676","article-title":"Phase I trial including pharmacokinetic and pharmacodynamic correlations of combinations paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer","volume":"17","author":"Belani","year":"1999","journal-title":"J Clin Oncol"},{"issue":"12\u201330","key":"10.1016\/j.lungcan.2007.02.003_bib5","first-page":"S12","article-title":"Paclitaxel (175mg\/m2) plus carboplatin versus paclitaxel (225mg\/m2) plus carboplatin in non-small-cell lung cancer: a randomized study","volume":"24","author":"Kosmidis","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib6","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2083::AID-CNCR6>3.0.CO;2-I","article-title":"Front-line treatment of advanced non-small-cell lung carcinoma with docetaxel and vinorelbine","volume":"83","author":"Kouroussis","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2007.02.003_bib7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO.1999.17.3.914","article-title":"Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multi-center phase II trial","volume":"17","author":"Georgoulias","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.1999.17.1.12","article-title":"Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced metastatic non-small-cell lung cancer","volume":"17","author":"Cardenal","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib9","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1200\/JCO.1999.17.11.3522","article-title":"Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project","volume":"17","author":"Crino","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JCO.1994.12.2.360","article-title":"Randomized study of vinorelbine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients","volume":"12","author":"Le Chevalier","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/oxfordjournals.annonc.a058687","article-title":"Vinorelbine plus cisplatin in advanced non-small-cell lung cancer: a randomized trial","volume":"5","author":"Depierre","year":"1994","journal-title":"Ann Oncol"},{"issue":"512\u2013514","key":"10.1016\/j.lungcan.2007.02.003_bib12","first-page":"S12","article-title":"Paclitaxel (1-h infusion) plus carboplatin in the treatment of advanced non-small-cell lung cancer: results of a multicenter phase II trial","volume":"24","author":"Greco","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib13","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/annonc\/mdh260","article-title":"Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial","volume":"15","author":"Stathopoulos","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib14","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.1999.17.9.2710","article-title":"Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer","volume":"17","author":"De Vore","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib15","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.bjc.6602827","article-title":"Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial","volume":"93","author":"Stathopoulos","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2007.02.003_bib16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2000.18.6.1351","article-title":"Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the International CATAPULTI Study Group","volume":"18","author":"Von Pawel","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib17","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib18","unstructured":"US Food and Drug Administration. FDA News; online February 5, 2004."},{"key":"10.1016\/j.lungcan.2007.02.003_bib19","doi-asserted-by":"crossref","unstructured":"Swainston HT, Scott LJ. Pemetrexed Am J Cancer 2003;2(5):359\u201370.","DOI":"10.2165\/00024669-200302050-00009"},{"key":"10.1016\/j.lungcan.2007.02.003_bib20","first-page":"1016","article-title":"Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts","volume":"6","author":"Teicher","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.lungcan.2007.02.003_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2217\/14796694.1.6.733","article-title":"Clinical activity of pemetrexed: a multi targeted antifolate anticancer agent","volume":"1","author":"Solomon","year":"2005","journal-title":"Future Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s002800000144","article-title":"Population pharmacokinetics of pemetrexed disodium (Alimta) in patients with cancer","volume":"46","author":"Oueller","year":"2000","journal-title":"Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib23","doi-asserted-by":"crossref","unstructured":"Awada A, Clark R, Dumez H, Gil T, et al. Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors. Proc [abstract 2053] Am Soc Clin Oncol 2004.","DOI":"10.1200\/jco.2004.22.90140.2053"},{"key":"10.1016\/j.lungcan.2007.02.003_bib24","doi-asserted-by":"crossref","unstructured":"Graefe T, Bolling C, Lubbing C, et al. Pemetrexed in combination with paclitaxel: a phase I clinical and pharmacokinetic trial in patients with solid tumors. Proc [abstract 2051] Am Soc Clin Oncol 2006.","DOI":"10.1200\/jco.2006.24.18_suppl.2051"},{"key":"10.1016\/j.lungcan.2007.02.003_bib25","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.1999.17.10.3009","article-title":"Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin","volume":"17","author":"Thodtmann","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib26","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1200\/JCO.1999.17.4.1194","article-title":"Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group","volume":"17","author":"Rusthoven","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdf115","article-title":"Phase II trial of pemetrexed disodium (Alimta, registered trademark LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer","volume":"13","author":"Clarke","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1008336931378","article-title":"Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514), pemetrexed disodium (ALIMTA) and cisplatin: a multi-center phase II trial","volume":"11","author":"Manegold","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/1097-0142(20010801)92:3<595::AID-CNCR1359>3.0.CO;2-D","article-title":"Arnold et al. Phase II study of pemetrexed antifolate, and cisplatin as first-line therapy in patients with advanced non-small-cell lung carcinoma: a study of the National Cancer Institute of Canada Trials Group","volume":"92","author":"Shepherd","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2007.02.003_bib30","first-page":"545","article-title":"Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy","volume":"1","author":"Niyikiza","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.lungcan.2007.02.003_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1634\/theoncologist.6-4-363","article-title":"Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors","volume":"6","author":"Hanauske","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2007.02.003_bib32","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/cncr.21480","article-title":"Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small-cell lung cancer","volume":"104","author":"Zinner","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2007.02.003_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 12","key":"10.1016\/j.lungcan.2007.02.003_bib34","first-page":"S12","article-title":"Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial","volume":"24","author":"Akerley","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib35","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1200\/JCO.1999.17.8.2316","article-title":"Cisplatin, gemcitabine and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study","volume":"17","author":"Frasci","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib36","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib37","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/cncr.10852","article-title":"Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated stage IIIB\/IV non-small-cell lung carcinoma","volume":"95","author":"Socinski","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2007.02.003_bib38","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.1997.15.1.297","article-title":"Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study","volume":"15","author":"Crino","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib39","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.1999.17.3.921","article-title":"Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer","volume":"17","author":"Iaffaioli","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.2000.18.3.623","article-title":"Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial","volume":"18","author":"Bonomi","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib41","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1023\/A:1008219125746","article-title":"Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer","volume":"8","author":"Miller","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.1997.15.1.317","article-title":"Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer","volume":"15","author":"Huizing","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.02.003_bib43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1997.15.1.304","article-title":"Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer (NSCLC)","volume":"15","author":"Oshita","year":"1997","journal-title":"J Clin Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500207001158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500207001158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T22:51:40Z","timestamp":1587423100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500207001158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0169500207001158"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2007.02.003","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}